Category: Laser/Light-based Devices
Vascular Solutions agrees to pay $520,000 to settle a U.S. Justice Dept. probe without admitting any wrongdoing.
Vascular Solutions (NSDQ:VASC) issued a special statement this week after the U.S. Justice announced that it had won a $520,000 settlement after accusing the company of selling a medical device without proper FDA approval.
Medtronic says it will pay up to $105 million to acquire Visualase and its MRI-guided neurosurgery laser device.
Medtronic (NYSE:MDT) said today that it paid up to $105 million to acquire Visualase and its MRI-guided laser neurosurgery device.
Wall Street rallies as dental laser maker Biolase raises $12 million through a private placement round, even as the company deals with an ongoing civil war involving ousted CEO Federico Pignatelli.
California-based Biolase (NSDQ:BIOL) announced today that it secured $12 million in a private placement funding round, even as the company weathers the internal tumult following the ouster of former CEO Federico Pignatelli.
Ousted Biolase CEO Federico Pignatelli launches an investigation into the device maker, saying he suspects "wrongdoing, mismanagement and corporate governance failures."
Shares of Biolase (NSDQ:BIOL) got a modest boost today, even as a company insider announced a far-reaching investigation into the company's management under the suspicion of wrongdoing.
Biolase CEO Federico Pignatelli is out after a court-ordered shake-up at Biolase.
The boardroom and C-suite at Biolase (NSDQ:BIOL) got a shake-up this week following a Delaware Supreme Court decision in a lawsuit filed by Oracle Partners earlier this year.
Biolase vows to amend its complaint after a federal judge shoots down its false advertising and defamation claims against rival dental laser maker Fotona.
A federal judge this month dismissed a Biolase (NSDQ:BIOL) lawsuit alleging false advertising and defamation by dental laser rival Fotona, but left the door open for an amended complaint.
Biolase steadies itself against a proxy war filed by activist majority shareholder Oracle Partners over alleged manipulation of the board of directors.